Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489707 · ClinicalTrials.gov registry record · NA
The Prevent Anal Cancer Self-Swab Study
A NA study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- NA
- Development phase
- 253
- Enrollment target
NCT03489707: Completed NA study, sponsored by Medical College of Wisconsin.
NCT03489707 is a NA study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 253 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03489707, a NA study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- NA
- Development phase
- 253 participants
- Enrollment target
Study Summary
The purpose of this research study is to find ways to screen for anal cancer among gay, bisexual, and other men who have sex with men (MSM) and transgender persons. This study will try to find out if persons will do annual anal cancer screening, what factors are associated with repeated screening, and how this affects a person's decision to have high-resolution anoscopy.
Primary Outcome
Compliance is assessed by the number of participants who provide specimens for annual anal HPV DNA screening
Interventions
- BEHAVIORAL Home-based human papillomavirus (HPV) DNA screening
- BEHAVIORAL Clinic-based human papillomavirus (HPV) DNA screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 253 participants |
| Start Date | 2020-01-09 |
| Est. Completion | 2023-08-31 |
| Phase | NA |
What the finished NCT03489707 record still lists
NCT03489707 is an interventional study that assigns participants to a tested intervention. The registered 253 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Home-based human papillomavirus (HPV) DNA screening is the first listed.
NCT03489707 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03489707 about?
NCT03489707 is a clinical study titled "The Prevent Anal Cancer Self-Swab Study". The purpose of this research study is to find ways to screen for anal cancer among gay, bisexual, and other men who have sex with men (MSM) and transgender persons. This study will try to find out if persons will do annual anal cancer screening, what factors are associated with repeated screening, a...
What is the current status of trial NCT03489707?
This trial is currently completed. It is a NA study. The enrollment target is 253 participants. The study started on 2020-01-09. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT03489707?
The interventions under investigation include: Home-based human papillomavirus (HPV) DNA screening (BEHAVIORAL), Clinic-based human papillomavirus (HPV) DNA screening (BEHAVIORAL).
Who is sponsoring clinical trial NCT03489707?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03489707's enrollment target sits among peer trials
253 407th of 2000 higher than 1,594 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI